Table 2 Safety and effectiveness in the surgery group (n = 21).
Characteristics | Surgery (n = 21) |
|---|---|
Time from last dose chemotherapy to surgery, days | Mean ± SD: 40.24 ± 11.19 IQR: 39.00 (32.00, 46.00) |
R0 resection | 100% |
n (%) with surgical approaches, | |
RATS lobectomy | 2 (9.5%) |
VATS lobectomy | 11 (52.3%) |
VATS bi-lobectomy | 2 (9.5%) |
VATS double sleeve resection (Bronchovascular) | 1 (4.8%) |
Lobectomy | 2 (9.5%) |
Tracheal sleeve resection | 1 (4.8%) |
Double sleeve resection (Bronchovascular) | 1 (4.8%) |
Intrapericardial bi-lobectomy | 1 (4.8%) |
Operation time, hours | Mean ± SD: 2.07 ± 0.62 IQR: 2.00 (1.50, 2.50) |
Intraoperative blood loss, mL | Mean ± SD: 63.81 ± 42.01 IQR: 50.00 (50.00, 50.00) |
Blood transfusion, mL | 0 (no one received blood transfusion) |
Hospitalization time, days | Mean ± SD: 5.38 ± 0.42 IQR: 5.00 (4.00, 7.00) |
Chest tube removal time, days | Mean ± SD: 11.67 ± 5.62 IQR: 11.00 (6.50, 15.00) |
30-days mortality | 0 |
90-days mortality | 0 |
n (%) with complications, | 4 (19.0%) |
Bronchopleural fistula | 2 (9.5%) |
Subcutaneous emphysema | 2 (9.5%) |
n (%) with residual viable tumour | |
0% | 9 (42.9%) |
0–10% | 4 (19.0%) |
> 10% | 8 (38.1%) |
Residual viable tumour, % | Mean ± SD: 18 ± 27 IQR: 5.00 (0.00, 20.00) |
Decrease in sum of lesion diameter, % | Mean ± SD: 59.84 ± 21.98 IQR: 62.48 (40.44, 78.78) |
n (%) with TNM downstaging | 17 (81.0%) |
n (%) with T downstaging | 19 (90.5%) |
n (%) with N downstaginga | 15 (71.4%) |
N3 to N0 | 3 (75.0%) |
N3 to N1 | 1 (25.0%) |
N2 to N0 | 3 (42.9%) |
N2 to N2 | 4 (57.2%) |
N1 to N0 | 8 (88.9%) |
N1 to N1 | 1 (11.1%) |
